Oncology Clinical Trials in Scarborough, ME

As of June 2026, 49 paid clinical trials are recruiting for Oncology in Scarborough, Maine. Oncology trials evaluate immunotherapies, targeted therapies, antibody-drug conjugates, and combination regimens across solid tumors and blood cancers — from early-phase first-in-human studies to phase 3 registration trials. Compensation typically covers time, travel, and study visits, and many studies also include study-related medical care at no cost.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: June 12, 2026.

Filter results

Filter results

State

City

Facility

Phase

Study type

Intervention

Recruitment status

Condition

Sex

Age

Healthy volunteers only

49 clinical trials for Oncology

·Clear filters·↓ Download CSV

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

for Lung Non-Small Cell Carcinoma

1150 locations incl. Anchorage

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT04267848·Phase 3·Recruiting

Apply to this trial

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

for Locally Advanced Solid Tumors

Drug: Repotrectinib

20 locations incl. Los Angeles

Sponsor: Turning Point Therapeutics, Inc.

Sex: All·Age: Up to 25

Code: NCT04094610·Phase 1, Phase 2·Recruiting

Apply to this trial

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

for B Acute Lymphoblastic Leukemia

203 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: All·Age: 365 Days - 25

Code: NCT03959085·Phase 3·Recruiting

Apply to this trial

Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer

for Breast Cancer

451 locations incl. Fairbanks

Sponsor: Canadian Cancer Trials Group

Sex: Female·Age: 35+

Code: NCT03488693·Phase 3·Recruiting

Apply to this trial

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

for Ganglioneuroblastoma

152 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: All·Age: 365 Days - 30

Code: NCT03126916·Phase 3·Recruiting

Apply to this trial

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

for Cancer, Metastatic

67 locations incl. Birmingham

Sponsor: Massive Bio, Inc.

Sex: All·Age: All ages

Code: NCT03452774·Recruiting

Apply to this trial

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

for Lymphoma, Non-Hodgkin

174 locations incl. Birmingham

Sponsor: American Society of Clinical Oncology

Sex: All·Age: 12+

Code: NCT02693535·Phase 2·Recruiting

Apply to this trial

Project: Every Child for Younger Patients With Cancer

for Adrenal Gland Pheochromocytoma

245 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: All·Age: Up to 25

Code: NCT02402244·Recruiting

Apply to this trial

Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment

for Hodgkin Lymphoma in Remission

69 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: All·Age: All ages

Code: NCT01790152·Recruiting

Apply to this trial

Conditions in Oncology (Scarborough, ME)

Breast cancer· 9 Acute myeloid leukemia (AML)· 8 Solid tumor· 8 Non-small cell lung cancer (NSCLC)· 7 Ovarian cancer· 6 Endometrial cancer· 4 Non-Hodgkin lymphoma· 4 Melanoma· 4 Metastatic breast cancer· 3 Chronic lymphocytic leukemia (CLL)· 3 Leukemia (other)· 3 Myelodysplastic syndromes (MDS)· 3 Hematologic malignancy· 3 HER2-positive breast cancer· 2 Prostate cancer· 2 Kidney cancer· 2 Acute lymphoblastic leukemia· 2 Myeloproliferative neoplasm· 2 Small lymphocytic lymphoma· 2 Osteosarcoma· 2 Neuroblastoma· 2 Cancer (any)· 2 Triple-negative breast cancer· 1 Colorectal cancer· 1 Gastroesophageal junction cancer· 1 Biliary tract cancer· 1 Bladder cancer· 1 Cervical cancer· 1 Fallopian tube cancer· 1 Glioblastoma· 1 Multiple myeloma· 1 Myelofibrosis· 1 Follicular lymphoma· 1 Mantle cell lymphoma· 1 Marginal zone lymphoma· 1 Head and neck cancer· 1 Sarcoma· 1 Neuroendocrine tumors· 1